Akebia Therapeutics repays $55 million loan in full
AKBA•Akebia Therapeutics repaid its $55 million BlackRock loan facility using proceeds from Symbiotic Capital’s initial $60 million tranche. The financing facility is worth up to $140 million, with an additional $80 million tranche available at Symbiotic’s discretion.
1. Loan repayment and terms
Akebia Therapeutics repaid its $55 million BlackRock loan facility in full using proceeds from Symbiotic Capital’s initial $60 million tranche. The senior secured term loan facility, which closed on November 12, 2026, is worth up to $140 million, with a further tranche of up to $80 million available at Symbiotic Capital’s discretion. It has a 60-month maturity and interest-only payments, with principal due at maturity; its variable monthly rate is the greater of WSJ Prime plus 4.5% or 11.5%.




